Durgical
EN
Open the app

Advanced heart failure: transplant and LVAD

When the heart keeps failing despite the best medicines, the options are a new heart, an implanted pump or comfort-focused care, and timing matters.

Updated

What it is

Advanced (stage D) heart failure means severe, persistent symptoms and heart dysfunction despite optimal medicines and devices, with repeated decompensations, poor exercise capacity or organ damage. The options are heart transplant, a durable left ventricular assist device (LVAD) as bridge or lifelong therapy, or palliative care.

Who gets it

Estimates of how many people with heart failure have advanced disease range from 0.2% to 14% depending on the definition, and only about half survive a year without advanced therapy. Use of transplants and mechanical support has stagnated worldwide, partly because patients are referred late. Heart transplant survival is about 90% at 1 year and about 80% at 5 years.

Causes

  • End stage of any cardiomyopathy: ischaemic, dilated, Chagas, hypertrophic, restrictive or infiltrative
  • Congenital heart disease that surgery cannot correct further
  • Ventricular arrhythmias that cannot be controlled
  • Failure to wean from temporary mechanical support after infarction or cardiac surgery

Risk factors

  • Inotropes needed now or in the past
  • NYHA class III–IV or persistently high natriuretic peptides
  • End-organ dysfunction: worsening kidney or liver function
  • Ejection fraction below 20%
  • Defibrillator shocks that recur
  • Heart failure admissions more than once in 12 months
  • Persistent oedema or escalating diuretic needs
  • Consistently low blood pressure
  • Prognostic medicines that cannot be up-titrated or must be reduced

Pathophysiology

As the failing ventricle remodels, output falls and filling pressures rise; congestion of the kidneys and liver and low blood pressure then limit the very medicines that slow the disease, so patients tolerate them less and decompensate more often. Once kidney, liver or lung-vessel damage becomes irreversible, transplant and LVAD are no longer possible, which is why referral must be early. A continuous-flow LVAD unloads the left ventricle: a rotor (magnetically levitated in current designs) pulls blood from the apex into the ascending aorta; only its speed can be set, flow is estimated from power use, and the native pulse becomes small or absent. The right ventricle is not supported, so right ventricular failure can starve the pump, and an underfilled ventricle can collapse onto the inflow cannula (a suction event). Anticoagulation, acquired von Willebrand deficiency and gastrointestinal arteriovenous malformations explain the frequent bleeding. A transplanted heart is denervated, so ischaemia from allograft vasculopathy is seldom painful.

Classification

  • Stage D (ACC/AHA) and HFA-ESC advanced heart failure
  • Durable LVAD: bridge to transplant, bridge to candidacy, bridge to recovery, or destination therapy
  • Temporary percutaneous support, used in hospital as a bridge to recovery, decision or a durable device
  • Heart transplantation (orthotopic)
  • Palliative and supportive care, alone or alongside other options

Symptoms and signs

  • Breathlessness at rest or with minimal effort
  • Fatigue, poor appetite and unintended weight loss (cardiac cachexia)
  • Persistent swelling despite rising diuretic doses
  • Dizziness from low blood pressure
  • Palpitations or ICD shocks

Diagnosis

Clinical
At every heart failure visit, screen for markers of advanced disease (inotropes, NYHA III–IV, end-organ dysfunction, very low EF, defibrillator shocks, repeated admissions, escalating diuretics, low blood pressure, medicines that cannot be up-titrated) and refer early to an advanced heart failure centre. In an LVAD patient, judge perfusion by mental state and skin, listen for the pump hum, read the controller and call the VAD team early, even at a hospital that did not implant the device.
Tests
Natriuretic peptides, kidney and liver function, sodium; cardiopulmonary exercise test; right heart catheterisation for filling pressures, cardiac output and pulmonary vascular resistance before transplant or LVAD. LVAD: mean arterial pressure by return-to-flow with a manual cuff or by arterial line, controller data (speed, power, estimated flow, pulsatility), haemolysis markers (LDH, haptoglobin, free haemoglobin), coagulation and cultures. Transplant: surveillance endomyocardial biopsy for rejection.
Imaging
Echocardiography for ventricular size, right ventricular function, valves and, with an LVAD, septal position and suction; CT angiography of the device (specific but insensitive for thrombus); coronary angiography with intravascular ultrasound for allograft vasculopathy.

Differential diagnosis

  • Reversible causes of worsening heart failure: ischaemia, valve disease, arrhythmia, poor adherence, harmful drugs
  • Constrictive pericarditis or restrictive cardiomyopathy
  • Non-cardiac causes of breathlessness and fatigue
  • Low blood pressure with an LVAD: low preload (bleeding, dehydration, right ventricular failure), high afterload, or pump malfunction

Unwell LVAD patient: which complication?

ProblemCluesControllerFirst steps
Bleeding (the most common)Black stools, nosebleeds, anaemiaLow flow if volume fallsResuscitate; agree reversal and transfusion with the VAD team
Pump thrombosisDark urine, high LDH and free haemoglobin, heart failureHigh-power spikes; no hum if completeAnticoagulation as directed by the VAD team; pump exchange as last resort
Driveline infectionFever, redness or discharge at the exit siteUsually normalCultures first, then broad-spectrum antibiotics
Suction event or right ventricular failureLow output; full IVC and high venous pressure if the RV failsLow-flow and low-pulsatility alarmsCautious fluids if underfilled; fluids can worsen RV failure
StrokeNew deficit or headacheOften normalUrgent brain imaging; plan anticoagulation with the VAD team

Goal of treatment

Recognise advanced disease early, refer before organs are irreversibly damaged, match each patient to transplant, LVAD or palliative care according to their goals, and manage device and graft problems with the specialist team.

Treatment

Follow-up
Early referral to an advanced heart failure centre when markers of advanced disease appear; multidisciplinary assessment with exercise testing and right heart catheterisation.
Surgical
Heart transplantation for eligible patients (usually under about 70, without irreversible pulmonary hypertension, active cancer, uncontrolled infection or active substance use), followed by lifelong immunosuppression, usually a calcineurin inhibitor and glucocorticoids after induction.
Surgical
Durable LVAD as a bridge to transplant or as destination therapy for those who cannot receive a heart; temporary percutaneous support in hospital as a bridge.
Medical
Long-term anticoagulation with an LVAD, balanced against bleeding; rejection after transplant treated with glucocorticoid pulses and, if needed, antithymocyte globulin.
Acute
Emergency care of an LVAD patient: assess perfusion, not pulse; check controller and connections; estimate mean arterial pressure by return-to-flow or arterial line; call the VAD team and transfer to an LVAD centre. If unresponsive with no perfusion (for example very low end-tidal CO2), start chest compressions; cardiovert or defibrillate as usual.
Conservative
Palliative and supportive care: symptom relief, advance care planning and discussion of resuscitation preferences with the patient and family.
Follow-up
After transplant: surveillance biopsies, infection and cancer surveillance, screening for allograft vasculopathy. With an LVAD: sterile driveline exit-site care, battery and controller checks, anticoagulation monitoring. Nursing: teach the patient and family how to answer alarms and care for the exit site.

Complications

  • LVAD: bleeding, especially gastrointestinal from arteriovenous malformations, and nosebleeds
  • LVAD: pump thrombosis with haemolysis
  • LVAD: driveline infection, the most common device infection
  • LVAD: stroke, ischaemic or haemorrhagic
  • LVAD: right ventricular failure, suction events and ventricular arrhythmias
  • Transplant: acute rejection (most common in the first months), infection, kidney damage from immunosuppressants
  • Transplant: cardiac allograft vasculopathy, often painless, and lymphoproliferative disease

Common traps

  • No palpable pulse in an LVAD patient means cardiac arrest: continuous flow often leaves no pulse; judge perfusion by mental state, skin, the pump hum, the controller and mean arterial pressure
  • Chest compressions will dislodge the pump: compressions are started when an LVAD patient is unresponsive with no perfusion; dislodgement has not been documented
  • VT in an LVAD patient is always unstable: the pump often maintains output and the patient may stay awake, but the right ventricle suffers, so the rhythm is still corrected
  • Transplant recipients feel angina when their coronaries narrow: the graft is denervated, so allograft vasculopathy usually shows as heart failure, arrhythmia or sudden death
  • Refer for transplant once the patient needs inotropes in intensive care: by then kidney, liver or lung-vessel damage may be irreversible; refer when the first markers of advanced disease appear

Prognosis

Without advanced therapies, about half of patients with advanced heart failure die within a year. After heart transplant about 90% survive one year and about 80% five years; early deaths are mostly rejection and infection, later ones allograft vasculopathy and lymphoproliferative disease. An LVAD can prolong life and improve its quality, but bleeding, infection and stroke are common.

Prevention

  • Optimising guideline-directed therapy early to slow progression
  • Screening heart failure patients for markers of advanced disease at each visit
  • LVAD: anticoagulation in range, blood pressure control and sterile driveline care
  • Transplant: strict adherence to immunosuppression and regular surveillance

Test yourself

Think of the answer, then tap the question to see it.

Why can an LVAD patient be well perfused without a palpable pulse?

A continuous-flow pump moves blood steadily from the LV apex to the aorta, so pulse pressure is small or absent although flow is adequate.

Which LVAD complication is suggested by high-power alarms, dark urine and a high LDH?

Pump thrombosis with haemolysis; call the VAD team and transfer to the implanting centre.

What is the most common complication of a durable LVAD?

Bleeding, often gastrointestinal from arteriovenous malformations, made worse by anticoagulation and acquired von Willebrand deficiency.

Why do heart transplant recipients rarely feel angina from allograft vasculopathy?

The transplanted heart is denervated, so ischaemia is often silent and shows up as heart failure, arrhythmia or sudden death.

Why should a patient with advanced heart failure be referred before needing inotropes in intensive care?

Transplant and LVAD need kidneys, liver and lung vessels that still recover; late referral can leave irreversible organ damage that rules both out.

Add to my cards (5)

Why it happens

Connections

Educational information, not medical advice. For any symptom, see a health professional.

Sources: Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC (European Journal of Heart Failure (Europe PMC), 2025); Chronic Heart Failure (MSD Manual Professional Edition, 2026); Heart Transplantation (MSD Manual Professional Edition, 2026); Heart transplant (MedlinePlus, US National Library of Medicine, 2026); Ventricular assist device (MedlinePlus, US National Library of Medicine, 2026); Continuous-flow left ventricular assist devices: Management in the emergency department (JACEP Open (Europe PMC), 2020); Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis (Croatian Medical Journal (Europe PMC), 2014).

← All conditions

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.